PRAXBIND (idarucizumab), antidote for dabigatran

No clinical benefit demonstrated when compared with current treatment

• PRAXBIND is a neutralising agent specific to the anticoagulant effect of dabigatran (PRADAXA).
• It is a humanized monoclonal antibody fragment that has Marketing Authorisation in adults treated with dabigatran etexilate when a rapid neutralisation of its anticoagulant effects is required due to a surgical emergency or urgent procedures, or in case of uncontrolled or life-threatening bleedings.
• From the available clinical data it is not possible to estimate the impact of PRAXBIND in terms of morbidity and mortality compared to current symptomatic treatments.